Chemical kinomics: A powerful strategy for target deconvolution

BMB Reports

Volumn 43, Issue 11, 2010, Pages 711-719

  Kim, Do Hee ^a   Sim, Taebo ^a  

^a Korea Institute of Science and Technology   (South Korea)

Author keywords

Chemical kinomics; Kinase inhibitor; Protein kinase; Target identification

Indexed keywords

BCR ABL PROTEIN; BCR ABL TYROSINE KINASE; BCR-ABL TYROSINE KINASE; GNF 2 COMPOUND; GNF-2 COMPOUND; PEPTIDE LIBRARY; PROTEIN KINASE; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; PYRIMIDINE DERIVATIVE;

ALLOSTERISM; ARTICLE; BIOLOGY; CHEMISTRY; DRUG ANTAGONISM; DRUG DEVELOPMENT; METABOLISM; PHOSPHORYLATION; SIGNAL TRANSDUCTION;

ALLOSTERIC REGULATION; COMPUTATIONAL BIOLOGY; DRUG DISCOVERY; FUSION PROTEINS, BCR-ABL; PEPTIDE LIBRARY; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; PROTEIN-TYROSINE KINASES; PYRIMIDINES; SIGNAL TRANSDUCTION;

EID: 78649790001     PISSN: 19766696     EISSN: 1976670X     Source Type: Journal    
DOI: 10.3858/BMBRep.2010.43.11.711     Document Type: Article

References (68)

1. Bossemeyer, D. (1995) Protein kinases- structure and function. FEBS Lett. 369, 57-61.
2. Fabbro, D. and Garcia-Echeverria, C. (2002) Targeting protein kinases in cancer therapy. Curr. Opin. Drug. Discov. Devel. 5, 701-712.
3. Fabbro, D., Ruetz, S., Buchdunger, E., Cowan-Jacob, S. W., Fendrich, G., Liebetanz, J., Mestan, J., O'Reilly, T., Traxler, P., Chaudhuri, B., Fretz, H., Zimmermann, J., Meyer, T., Caravatti, G., Furet, P. and Manley, P. W. (2002) Protein kinases as targets for anticancer agents: from inhibitors to useful drugs. Pharmacol. Ther. 93, 79-98.
4. Kim, J. A. (2003) Targeted therapies for the treatment of cancer. Am. J. Surg. 186, 264-268.
5. Manning, G., Whyte, D. B., Martinez, R., Hunter, T. and Sudarsanam, S. (2002) The protein kinase complement of the human genome. Science 298, 1912-1934.
6. Zhang, J., Yang, P. L. and Gray, N. S. (2009) Targeting cancer with small molecule kinase inhibitors. Nat. Rev. Cancer 9, 28-39.
7. Cohen, P. (2002) Protein kinases- the major drug targets of the twenty-first century? Nat. Rev. Drug Discov. 1, 309-315.
8. Jeffery, D. A. and Bogyo, M. (2003) Chemical proteomics and its application to drug discovery. Curr. Opin. Biotechnol. 14, 87-95.
9. Salemme, F. R. (2003) Chemical genomics as an emerging paradigm for postgenomic drug discovery. Pharmacogenomics 4, 257-267.
10. Rix, U., Hantschel, O., Durnberger, G., Remsing Rix, L. L., Planyavsky, M., Fernbach, N. V., Kaupe, I., Bennett, K. L., Valent, P., Colinge, J., Kocher, T. and Superti-Furga, G. (2007) Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. Blood 110, 4055-4063.
11. Li, J., Rix, U., Fang, B., Bai, Y., Edwards, A., Colinge, J., Bennett, K. L., Gao, J., Song, L., Eschrich, S., Superti-Furga, G., Koomen, J. and Haura, E. B. (2010) A chemical and phosphoproteomic characterization of dasatinib action in lung cancer. Nat. Chem. Biol. 6, 291-299.
12. Hunter, T. (1995) Protein kinases and phosphatases: the yin and yang of protein phosphorylation and signaling. Cell 80, 225-236.
13. Johnson, L. N. and Lewis, R. J. (2001) Structural basis for control by phosphorylation. Chem. Rev. 101, 2209-2242.
14. Ostman, A. and Bohmer, F. D. (2001) Regulation of receptor tyrosine kinase signaling by protein tyrosine phosphatases. Trends Cell Biol. 11, 258-266.
15. Richardson, C. J., Gao, Q., Mitsopoulous, C., Zvelebil, M., Pearl, L. H. and Pearl, F. M. (2009) MoKCa databasemutations of kinases in cancer. Nucleic. Acids. Res. 37, D824-831.
16. Johnson, L. N., Noble, M. E. and Owen, D. J. (1996) Active and inactive protein kinases: structural basis for regulation. Cell 85, 149-158.
17. Scapin, G. (2002) Structural biology in drug design: se lective protein kinase inhibitors. Drug Discov. Today 7, 601-611.
18. Grant, S. K. (2009) Therapeutic protein kinase inhibitors. Cell. Mol. Life Sci. 66, 1163-1177.
19. Croston, G. E. (2002) Functional cell-based uHTS in chemical genomic drug discovery. Trends Biotechnol. 20, 110-115.
20. Graves, P. R. and Haystead, T. A. (2002) Molecular biologist's guide to proteomics. Microbiol. Mol. Biol. Rev. 66, 39-63
21. Zheng, X. S., Chan, T. F. and Zhou, H. H. (2004) Genetic and genomic approaches to identify and study the targets of bioactive small molecules. Chem. Biol. 11, 609-618.
22. Cravatt, B. F., Wright, A. T. and Kozarich, J. W. (2008) Activity-based protein profiling: from enzyme chemistry to proteomic chemistry. Annu. Rev. Biochem. 77, 383-414.
23. Speers, A. E. and Cravatt, B. F. (2004) Chemical strategies for activity-based proteomics. Chembiochem 5, 41-47.
24. Patricelli, M. P., Szardenings, A. K., Liyanage, M., Nomanbhoy, T. K., Wu, M., Weissig, H., Aban, A., Chun, D., Tanner, S. and Kozarich, J. W. (2007) Functional interrogation of the kinome using nucleotide acyl phosphates. Biochemistry 46, 350-358.
25. Adam, G. C., Burbaum, J., Kozarich, J. W., Patricelli, M. P. and Cravatt, B. F. (2004) Mapping enzyme active sites in complex proteomes. J. Am. Chem. Soc. 126, 1363-1368.
26. Liu, Y., Jiang, N., Wu, J., Dai, W. and Rosenblum, J. S. (2007) Polo-like kinases inhibited by wortmannin. Labeling site and downstream effects. J. Biol. Chem. 282, 2505-2511.
27. Liu, Y., Shreder, K. R., Gai, W., Corral, S., Ferris, D. K. and Rosenblum, J. S. (2005) Wortmannin, a widely used phosphoinositide 3-kinase inhibitor, also potently inhibits mammalian polo-like kinase. Chem. Biol. 12, 99-107.
28. Wymann, M. P., Bulgarelli-Leva, G., Zvelebil, M. J., Pirola, L., Vanhaesebroeck, B., Waterfield, M. D. and Panayotou, G. (1996) Wortmannin inactivates phosphoinositide 3-kinase by covalent modification of Lys-802, a residue involved in the phosphate transfer reaction. Mol. Cell. Biol. 16, 1722-1733.
29. Wolf-Yadlin, A., Sevecka, M. and MacBeath, G. (2009) Dissecting protein function and signaling using protein microarrays. Curr. Opin. Chem. Biol. 13, 398-405.
30. Min, D. H. and Mrksich, M. (2004) Peptide arrays: towards routine implementation. Curr. Opin. Chem. Biol. 8, 554-558.
31. Reimer, U., Reineke, U. and Schneider-Mergener, J. (2002) Peptide arrays: from macro to micro. Curr. Opin. Biotechnol. 13, 315-320.
32. Schutkowski, M., Reineke, U. and Reimer, U. (2005) Peptide arrays for kinase profiling. Chembiochem 6, 513-521.
33. Hilhorst, R., Houkes, L., van den Berg, A. and Ruijtenbeek, R. (2009) Peptide microarrays for detailed, highthroughput substrate identification, kinetic characterization, and inhibition studies on protein kinase A. Anal. Biochem. 387, 150-161.
34. Houseman, B. T., Huh, J. H., Kron, S. J. and Mrksich, M. (2002) Peptide chips for the quantitative evaluation of protein kinase activity. Nat. Biotechnol. 20, 270-274.
35. Wang, Z. (2009) The peptide microarray-based assay for kinase functionality and inhibition study. Methods Mol. Biol. 570, 329-337.
36. Li, T., Liu, D. and Wang, Z. (2009) Microarray-based Raman spectroscopic assay for kinase inhibition by gold nanoparticle probes. Biosens. Bioelectron. 24, 3335-3339.
37. Wang, Z., Levy, R., Fernig, D. G. and Brust, M. (2006) Kinase-catalyzed modification of gold nanoparticles: a new approach to colorimetric kinase activity screening. J. Am. Chem. Soc. 128, 2214-2215.
38. Smith, G. P. (1985) Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. Science 228, 1315-1317.
39. Fabian, M. A., Biggs, W. H., 3rd, Treiber, D. K., Atteridge, C. E., Azimioara, M. D., Benedetti, M. G., Carter, T. A., Ciceri, P., Edeen, P. T., Floyd, M., Ford, J. M., Galvin, M., Gerlach, J. L., Grotzfeld, R. M., Herrgard, S., Insko, D. E., Insko, M. A., Lai, A. G., Lelias, J. M., Mehta, S. A., Milanov, Z. V., Velasco, A. M., Wodicka, L. M., Patel, H. K., Zarrinkar, P. P. and Lockhart, D. J. (2005) A small molecule-kinase interaction map for clinical kinase inhibitors. Nat. Biotechnol. 23, 329-336.
40. Dunn, J. J. and Studier, F. W. (1983) Complete nucleotide sequence of bacteriophage T7 DNA and the locations of T7 genetic elements. J. Mol. Biol. 166, 477-535.
41. Son, M., Hayes, S. J. and Serwer, P. (1988) Concatemerization and packaging of bacteriophage T7 DNA in vitro: determination of the concatemers' length and appearance kinetics by use of rotating gel electrophoresis. Virology 162, 38-46.
42. Griffin, J. D. (2005) Interaction maps for kinase inhibitors. Nat. Biotechnol. 23, 308-309.
43. Bantscheff, M., Eberhard, D., Abraham, Y., Bastuck, S., Boesche, M., Hobson, S., Mathieson, T., Perrin, J., Raida, M., Rau, C., Reader, V., Sweetman, G., Bauer, A., Bouwmeester, T., Hopf, C., Kruse, U., Neubauer, G., Ramsden, N., Rick, J., Kuster, B. and Drewes, G. (2007) Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. Nat. Biotechnol. 25, 1035-1044.
44. Gygi, S. P., Rist, B., Gerber, S. A., Turecek, F., Gelb, M. H. and Aebersold, R. (1999) Quantitative analysis of complex protein mixtures using isotope-coded affinity tags. Nat. Biotechnol. 17, 994-999.
45. Peters, E. C. and Gray, N. S. (2007) Chemical proteomics identifies unanticipated targets of clinical kinase inhibitors. ACS Chem. Biol. 2, 661-664.
46. Becker, F., Murthi, K., Smith, C., Come, J., Costa-Roldan, N., Kaufmann, C., Hanke, U., Degenhart, C., Baumann, S., Wallner, W., Huber, A., Dedier, S., Dill, S., Kinsman, D., Hediger, M., Bockovich, N., Meier-Ewert, S., Kluge, A. F. and Kley, N. (2004) A three-hybrid approach to scanning the proteome for targets of small molecule kinase inhibitors. Chem. Biol. 11, 211-223.
47. Abida, W. M., Carter, B. T., Althoff, E. A., Lin, H. and Cornish, V. W. (2002) Receptor-dependence of the transcription read-out in a small molecule three-hybrid system. Chembiochem 3, 887-895.
48. Gallagher, S. S., Miller, L. W. and Cornish, V. W. (2007) An orthogonal dexamethasone-trimethoprim yeast threehybrid system. Anal. Biochem. 363, 160-162.
49. Spencer, D. M., Wandless, T. J., Schreiber, S. L. and Crabtree, G. R. (1993) Controlling signal transduction with synthetic ligands. Science 262, 1019-1024.
50. Caligiuri, M., Molz, L., Liu, Q., Kaplan, F., Xu, J. P., Majeti, J. Z., Ramos-Kelsey, R., Murthi, K., Lievens, S., Tavernier, J. and Kley, N. (2006) MASPIT: three-hybrid trap for quantitative proteome fingerprinting of small moleculeprotein interactions in mammalian cells. Chem. Biol. 13, 711-722.
51. Jester, B. W., Cox, K. J., Gaj, A., Shomin, C. D., Porter, J. R. and Ghosh, I. (2010) A coiled-coil enabled split-luciferase three-hybrid system: applied toward profiling inhibitors of protein kinases. J. Am. Chem. Soc. 132, 11727-11735.
52. Okram, B., Nagle, A., Adrian, F. J., Lee, C., Ren, P., Wang, X., Sim, T., Xie, Y., Xia, G., Spraggon, G., Warmuth, M., Liu, Y. and Gray, N. S. (2006) A general strategy for creating "inactive-conformation" abl inhibitors. Chem. Biol. 13, 779-786.
53. Simard, J. R., Getlik, M., Grutter, C., Pawar, V., Wulfert, S., Rabiller, M. and Rauh, D. (2009) Development of a fluorescent-tagged kinase assay system for the detection and characterization of allosteric kinase inhibitors. J. Am. Chem. Soc. 131, 13286-13296.
54. de Lorimier, R. M., Smith, J. J., Dwyer, M. A., Looger, L. L., Sali, K. M., Paavola, C. D., Rizk, S. S., Sadigov, S., Conrad, D. W., Loew, L. and Hellinga, H. W. (2002) Construction of a fluorescent biosensor family. Protein Sci. 11, 2655-2675.
55. Torkamani, A., Kannan, N., Taylor, S. S. and Schork, N. J. (2008) Congenital disease SNPs target lineage specific structural elements in protein kinases. Proc. Natl. Acad. Sci. U.S.A. 105, 9011-9016.
56. Simard, J. R., Kluter, S., Grutter, C., Getlik, M., Rabiller, M., Rode, H. B. and Rauh, D. (2009) A new screening assay for allosteric inhibitors of cSrc. Nat. Chem. Biol. 5, 394-396.
57. Kung, C., Kenski, D. M., Dickerson, S. H., Howson, R. W., Kuyper, L. F., Madhani, H. D. and Shokat, K. M. (2005) Chemical genomic profiling to identify intracellular targets of a multiplex kinase inhibitor. Proc. Natl. Acad. Sci. U.S.A. 102, 3587-3592.
58. Hunter, T. and Plowman, G. D. (1997) The protein kinases of budding yeast: six score and more. Trends Biochem. Sci. 22, 18-22.
59. Bishop, A. C., Ubersax, J. A., Petsch, D. T., Matheos, D. P., Gray, N. S., Blethrow, J., Shimizu, E., Tsien, J. Z., Schultz, P. G., Rose, M. D., Wood, J. L., Morgan, D. O. and Shokat, K. M. (2000) A chemical switch for inhibitor-sensitive alleles of any protein kinase. Nature 407, 395-401.
60. Nagar, B., Hantschel, O., Seeliger, M., Davies, J. M., Weis, W. I., Superti-Furga, G. and Kuriyan, J. (2006) Organization of the SH3-SH2 unit in active and inactive forms of the c-Abl tyrosine kinase. Mol. Cell. 21, 787-798.
61. Schindler, T., Bornmann, W., Pellicena, P., Miller, W. T., Clarkson, B. and Kuriyan, J. (2000) Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science 289, 1938-1942.
62. Cowan-Jacob, S. W., Guez, V., Fendrich, G., Griffin, J. D., Fabbro, D., Furet, P., Liebetanz, J., Mestan, J. and Manley, P. W. (2004) Imatinib (STI571) resistance in chronic myelogenous leukemia: molecular basis of the underlying mechanisms and potential strategies for treatment. Mini Rev. Med. Chem. 4, 285-299.
63. Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N. and Sawyers, C. L. (2001) Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293, 876-880.
64. von Bubnoff, N., Schneller, F., Peschel, C. and Duyster, J. (2002) BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study. Lancet 359, 487-491.
65. Wong, S. and Witte, O. N. (2004) The BCR-ABL story: bench to bedside and back. Annu. Rev. Immunol. 22, 247-306.
66. Adrian, F. J., Ding, Q., Sim, T., Velentza, A., Sloan, C., Liu, Y., Zhang, G., Hur, W., Ding, S., Manley, P., Mestan, J., Fabbro, D. and Gray, N. S. (2006) Allosteric inhibitors of Bcr-abl-dependent cell proliferation. Nat. Chem. Biol. 2, 95-102.
67. Zhang, J., Adrian, F. J., Jahnke, W., Cowan-Jacob, S. W., Li, A. G., Iacob, R. E., Sim, T., Powers, J., Dierks, C., Sun, F., Guo, G. R., Ding, Q., Okram, B., Choi, Y., Wojciechowski, A., Deng, X., Liu, G., Fendrich, G., Strauss, A., Vajpai, N., Grzesiek, S., Tuntland, T., Liu, Y., Bursulaya, B., Azam, M., Manley, P. W., Engen, J. R., Daley, G. Q., Warmuth, M. and Gray, N. S. (2010) Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors. Nature 463, 501-506.
68. Wales, T. E. and Engen, J. R. (2006) Hydrogen exchange mass spectrometry for the analysis of protein dynamics. Mass Spectrom. Rev. 25, 158-170.